Stability of nafamostat in intravenous infusion solutions, human whole blood and extracted plasma: implications for clinical effectiveness studies

被引：1

作者：

Hernandez-Mitre, Maria Patricia ^{[1
]}

Won, Hayoung ^{[1
]}

Wallis, Steven C. ^{[1
]}

Parker, Suzanne L. ^{[1
]}

Roberts, Jason A. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Queensland, Fac Med, UQ Ctr Clin Res, Brisbane 4029, Australia

[2] Metro North Hlth, Herston Infect Dis Inst HeIDI, Brisbane 4029, Australia

[3] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane 4029, Australia

[4] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane 4029, Australia

[5] Nimes Univ Hosp, Univ Montpellier, Div Anaesthesiol Crit Care Emergency & Pain Med, F-30029 Nimes, France

来源：

BIOANALYSIS | 2023年 / 15卷 / 12期

基金：

英国医学研究理事会;

关键词：

blood sample collection; degradation; hydrolysis; nafamostat; stability;

D O I：

10.4155/bio-2023-0040

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Aim: To describe the stability of nafamostat in infusion solutions, during blood sample collection and in extracted plasma samples in the autosampler. Methods: Nafamostat infusion solutions were stored at room temperature in the light for 24 h. For sample collection stability, fresh blood spiked with nafamostat was subjected to combinations of anticoagulants, added esterase inhibitor and temperature. Nafamostat was monitored in the extracted plasma samples in the autosampler. Results: Nafamostat was stable in infusion solutions. Nafamostat in whole blood was stable for 3 h before centrifugation when collected in sodium fluoride/potassium oxalate tubes (4 degrees C). Nafamostat in extracted plasma samples degraded at 4.7 +/- 0.7% per h. Conclusion: Viable samples can be obtained using blood collection tubes with sodium fluoride, chilling and processing promptly.

引用

页码：673 / 681

页数：9

共 11 条

[1] A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study [J].

Cao, Yan-guang ;

Zhang, Ming ;

Yu, Dan ;

Shao, Jing-ping ;

Chen, Yuan-cheng ;

Liu, Xiao-quan .

ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2008, 391 (03) :1063-1071

[2]

Denholm JT., 2022, RES SQ, V23, P1, DOI DOI 10.21203/RS.3.RS-1045085/V1

[3] Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review [J].

Hernandez-Mitre, Maria Patricia ;

Tong, Steven Y. C. ;

Denholm, Justin T. ;

Dore, Gregory J. ;

Bowen, Asha C. ;

Lewin, Sharon R. ;

Venkatesh, Balasubramanian ;

Hills, Thomas E. ;

McQuilten, Zoe ;

Paterson, David L. ;

Morpeth, Susan C. ;

Roberts, Jason A. .

CLINICAL PHARMACOKINETICS, 2022, 61 (10) :1331-1343

[4] Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 [J].

Hoffmann, Markus ;

Schroeder, Simon ;

Kleine-Weber, Hannah ;

Mueller, Marcel A. ;

Drosten, Christian ;

Poehlmann, Stefan .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (06)

[5] Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia [J].

Ikeda, Mahoko ;

Okugawa, Shu ;

Kashiwabara, Kosuke ;

Moritoyo, Takashi ;

Kanno, Yoshiaki ;

Jubishi, Daisuke ;

Hashimoto, Hideki ;

Okamoto, Koh ;

Tsushima, Kenji ;

Uchida, Yasuki ;

Mitsumura, Takahiro ;

Igari, Hidetoshi ;

Tsutsumi, Takeya ;

Araoka, Hideki ;

Yatera, Kazuhiro ;

Yamamoto, Yoshihiro ;

Nakamura, Yuki ;

Otani, Amato ;

Yamashita, Marie ;

Wakimoto, Yuji ;

Shinohara, Takayuki ;

Adachi-Katayama, Maho ;

Oyabu, Tatsunori ;

Kanematsu, Aoi ;

Harada, Sohei ;

Takeshita, Yuichiro ;

Nakano, Yasutaka ;

Miyazaki, Yasunari ;

Sakao, Seiichiro ;

Saito, Makoto ;

Ogura, Sho ;

Yamasaki, Kei ;

Kawasuji, Hitoshi ;

Hataji, Osamu ;

Inoue, Jun-Ichiro ;

Seto, Yasuyuki ;

Moriya, Kyoji .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 128 :355-363

[6] Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells [J].

Ko, Meehyun ;

Jeon, Sangeun ;

Ryu, Wang-Shick ;

Kim, Seungtaek .

JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (03) :1403-1408

[7]

Oh HS., 2022, MOLECULES, V27, P1

[8] Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics [J].

Quinn, Tom M. ;

Gaughan, Erin E. ;

Bruce, Annya ;

Antonelli, Jean ;

O'Connor, Richard ;

Li, Feng ;

McNamara, Sarah ;

Koch, Oliver ;

MacKintosh, Claire ;

Dockrell, David ;

Walsh, Timothy ;

Blyth, Kevin G. ;

Church, Colin ;

Schwarze, Juergen ;

Boz, Cecilia ;

Valanciute, Asta ;

Burgess, Matthew ;

Emanuel, Philip ;

Mills, Bethany ;

Rinaldi, Giulia ;

Hardisty, Gareth ;

Mills, Ross ;

Findlay, Emily Gwyer ;

Jabbal, Sunny ;

Duncan, Andrew ;

Plant, Sinead ;

Marshall, Adam D. L. ;

Young, Irene ;

Russell, Kay ;

Scholefield, Emma ;

Nimmo, Alastair F. ;

Nazarov, Islom B. ;

Churchill, Grant C. ;

McCullagh, James S. O. ;

Ebrahimi, Kourosh H. ;

Ferrett, Colin ;

Templeton, Kate ;

Rannard, Steve ;

Owen, Andrew ;

Moore, Anne ;

Finlayson, Keith ;

Shankar-Hari, Manu ;

Norrie, John ;

Parker, Richard A. ;

Akram, Ahsan R. ;

Anthony, Daniel C. ;

Dear, James W. ;

Hirani, Nik ;

Dhaliwal, Kevin .

EBIOMEDICINE, 2022, 76

[9] The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner [J].

Yamamoto, Mizuki ;

Kiso, Maki ;

Sakai-Tagawa, Yuko ;

Iwatsuki-Horimoto, Kiyoko ;

Imai, Masaki ;

Takeda, Makoto ;

Kinoshita, Noriko ;

Ohmagari, Norio ;

Gohda, Jin ;

Semba, Kentaro ;

Matsuda, Zene ;

Kawaguchi, Yasushi ;

Kawaoka, Yoshihiro ;

Inoue, Jun-ichiro .

VIRUSES-BASEL, 2020, 12 (06)

[10]

Yamaori S, 2006, DRUG METAB PHARMACOK, V21, P147, DOI 10.2133/dmpk.21.147

← 1 2 →